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Abstract
Isolated generalized dystonia is a central motor network disorder characterized by twisted movements or postures. The
most frequent genetic cause is a GAG deletion in the Tor1a (DYT1) gene encoding torsinA with a reduced penetrance
of 30-40 % suggesting additional genetic or environmental modifiers. Development of dystonia-like movements after a
standardized peripheral nerve crush lesion in wild type (wt) and Tor1a+/- mice, that express 50 % torsinA only, was
assessed by scoring of hindlimb movements during tail suspension, by rotarod testing and by computer-assisted gait
analysis. Western blot analysis was performed for dopamine transporter (DAT), D1 and D2 receptors from striatal and
quantitative RT-PCR analysis for DAT from midbrain dissections. Autoradiography was used to assess the functional DAT
binding in striatum. Striatal dopamine and its metabolites were analyzed by high performance liquid chromatography.
After nerve crush injury, we found abnormal posturing in the lesioned hindlimb of both mutant and wt mice
indicating the profound influence of the nerve lesion (15x vs. 12x relative to control) resembling human peripheral
pseudodystonia. In mutant mice the phenotypic abnormalities were increased by about 40 % (p < 0.05). This was
accompanied by complex alterations of striatal dopamine homeostasis. Pharmacological blockade of dopamine
synthesis reduced severity of dystonia-like movements, whereas treatment with L-Dopa aggravated these but only in
mutant mice suggesting a DYT1 related central component relevant to the development of abnormal involuntary
movements. Our findings suggest that upon peripheral nerve injury reduced torsinA concentration and environmental
stressors may act in concert in causing the central motor network dysfunction of DYT1 dystonia.
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Introduction
Dystonia is a clinical syndrome characterized by
sustained or intermittent muscle contractions causing
abnormal, often repetitive, movements, postures, or
both. According to the most recent consensus-based
definition, dystonic movements are typically patterned
and twisting, may be tremulous and are often initiated
or worsened by voluntary action and associated with
overflow muscle activation [2]. Epidemiological studies
implicate that more than 3 million people worldwide are
suffering from dystonia [25].
Etiologically, dystonia has multiple acquired and
genetic factors most likely converging to a multistep
pathophysiological pathway leading to a central motor
network disorder with a dystonic phenotype [26, 37].
DYT1 is the most common form of inherited dystonia
and is linked to a GAG deletion on the torsinA encoding
gene Tor1a. The penetrance of the typical human limb
onset generalized DYT1 dystonia phenotype is present
in only 30-40 % of gene carriers [28]. Because dystonia
can also be caused by a trauma [24, 51, 57] or by repeti-
tive limb overuse, and in the absence of a known genetic
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cause, the “two-hit” hypothesis for developing dystonia
has emerged. This is thought to involve intrinsic
predisposition and environmental triggers acting in
concert [30]. In a pharmacological mouse model of
DYT12 dystonia the dystonic phenotype was provoked
by electrical stress [8]. A non-genetic animal model for
blepharospasm was created by combined toxin induced
striatal dopamine (DA) depletion and lesioning of the
zygomatic nerve [46].
We hypothesized that a peripheral nerve injury tempor-
arily disrupting sensorimotor integration in the affected
limb may elicit focal dystonia in genetically predisposed
individuals. Several genetic alterations of the Tor1a gene
have been introduced into mice generating models for
DYT1 dystonia. These animals either lack the typical
dystonic phenotype [49, 53] or have only subtle motor def-
icits dissimilar to the human clinical presentation [14, 20]
or they suffer from neurodegeneration [31, 38] unlike
human DYT1 brains at post-mortem [17, 39, 45]. To
investigate the role of peripheral stressors we specifically
chose the Tor1a+/- mouse model since it does not develop
overt dystonia nor any signs of neurodegeneration. It has
been shown that the Tor1a+/- mouse produces only 50 %
torsinA and that the mutated torsinA exhibits loss of func-
tion [19, 54]. We here demonstrate that a peripheral nerve
lesion can elicit dystonia-like movements in wild type (wt)
and mutant mice. Only Tor1a+/- mice, however, demon-
strate a centrally mediated component of dystonia-like
movements as indicated by several biomarkers of striatal
dopaminergic dysregulation and by showing a treatment
response to DA depletion therapy.
Materials and methods
Animals
Heterozygous Tor1a knockout mice (Tor1a+/-) [19] and
wild type (wt) littermates of a mixed C57BL/6 J and 129
background were purchased from the Jackson Laboratory
(described as B6; 129-Tor1atm1Wtd/J, strain 006251) and
bred in our animal facility. Determination of the genotype
was performed by PCR according to the protocol from the
Jackson Laboratory using the following primers: a) mutant
forward: CGGTCGCTACCATTACCAGT; b) wt forward:
GCTGGCACGCCTTATTACTC. A common reverse pri-
mer was used: TAGAGCTCTGGGCTTGGAAA. These
primers resulted in following band sizes: knockout
1600 bp, wt 308 bp (Additional file 1: Fig. S1 a). Each PCR
was performed in a volume of 25 μl using a Hot Start PCR
Master Mix. We used the following PCR protocol: 95 °C,
5 min; 95 °C, 30 s; 65 °C, 1 min; 72 °C, 2 min; 39 cycles,
72 °C, 5 min. Analyses were performed on mice with an
average body weight of 25 g investigated at the age of
4 months. Mice were not randomized and were selected
on availability including both male and female (Additional
file 1: Fig. S1 b). Possible gender differences were analyzed
post hoc, but no significant difference was found in any of
the experiments.
Behavioral studies
Severity rating of dystonia-like movements
Frequency and duration of dystonia-like movements of
the affected right hindlimb were assessed during a 30 s
tail suspension test using a self-developed 0-4 point
scoring system (dystonia-like movement scale; DLMS).
The DLMS was rated from video clips (30 s) of the tail
suspension test by two observers (C.W.I. and B.B.T.)
blinded to the group assignment and timepoint to assure
an objective outcome assessment. Reported DLMS
scores reflect the mean of the two independent ratings:
0: no abnormal movement (Additional file 2: Suppl.
video 1); 1: short hindlimb retraction and clenching of
the foot only once during 30 s period (Additional file 3:
Suppl. video 2); 2: repeated hindlimb retraction and
clenching of the foot each episode lasting < 1 s (Additional
file 4: Suppl. video 3); 3: repeated hindlimb retraction
and foot clenching episodes lasting ≥ 1 and < 2 s. 4 (Add-
itional file 5: Suppl. video 4): repeated hindlimb retrac-
tion and foot clenching with episodes lasting ≥ 2 s and
hindlimb drawn up to the abdomen (Additional file 6:
Suppl. video 5).
Rotarod performance test
Mice were tested 3 times per session on a rotarod
(RotaRod Advanced, TSE systems) with accelerating
speed from 5 to 50 rpm for up to 300 s. Animal falls and
latencies to fall were recorded.
CatWalk XT gait analysis
Mice were placed on one side of the CatWalk XT (Noldus,
Wageningen, Netherlands) transparent glass runway and
were motivated by food pellet rewards to run to the other
side. Gait and footprints were recorded by a video camera
located underneath the animals. Three runs per animal
were analyzed (program version 10.0.408). Animals were
excluded from gait analysis if they stopped when walking
through the area of recording.
Sciatic nerve crush injury
Under deep anesthesia with ketamine-xylazine the
gluteal region of the right hind paw was shaved and
incised under sterile condition. The right sciatic nerve
was exposed and crushed at the region of the sciatic
notch by using a non-serrated clamp that was placed
around the isolated nerve with a constant and reprodu-
cible pressure for 30 s. Sham operated animals received
the same surgery but without crush.
Ip et al. Acta Neuropathologica Communications  (2016) 4:108 Page 2 of 14
Injection of L-3,4-dihydroxyphenylalanine (L-Dopa)/ben-
serazide and alpha-methyl-p-tyrosine (AMPT)
AMPT dissolved in normal saline was i.p. injected three
times within 24 h once weekly until week 8 at a dose of
100 mg/kg bodyweight per injection 24, 20 and 4 h
before behavioral testing was done as described [55].
Benserazide, a DOPA decarboxylase inhibitor, was
dissolved in saline and i.p. injected at a dose of 12 mg/
kg/day 15 min before i.p. administration of 30 mg/kg/
day L-Dopa once daily as described [52] until week 8
after sciatic crush.
Nerve conduction studies
Recordings were done on a digital Neurosoft-Evidence 3102
electromyograph (Schreiber & Tholen Medizintechnik) as
described [29]. In brief, after i.p. anaesthesia with
ketamine/xylazine (10:1; 10 μl/g body weight) supra-
maximal stimulation of the tibial nerve was done with
needle electrodes above the ankle (distal) and of the
sciatic nerve at the sciatic notch proximal to the lesion
site (about 34 °C skin temperature). Compound muscle
action potentials (CMAP) were recorded at the foot
muscles with steel needle electrodes. Peak to peak
CMAP amplitudes were determined. Latencies were
measured and the corresponding nerve conduction
velocities (NCV) were calculated. The investigators
(D.K. and K.V.T.) were not aware of the genotype of
the analyzed mice.
Immunohistochemistry and tissue analysis
Eight weeks after nerve crush or sham operation mice
were transcardially perfused with 0.1 M phosphate
buffered saline (PBS) at room temperature (RT). Freshly
dissected mouse brain, lumbar spinal cord (L2-L4) and
right sciatic nerve were snap frozen in liquid nitrogen-
cooled isopentane. Ten μm transverse cryosections of
the sciatic nerve, the spinal cord and coronal sections of
the brain at the region of 0.38 mm relative to the
bregma were cut for further staining (Paxinos and
Franklin, The Mouse Brain in Stereotaxic Coordinates,
2001, Fig. 28). The following antibodies were applied be-
fore using the ABC-system (Dako, Hamburg, Germany)
with 3,30-diaminobenzidine as peroxidase substrate:
chicken anti mouse MPZ (myelin protein zero) (Acris
Antibodies, Rockville, USA), mouse anti neurofilament
68 kDa (Sigma-Aldrich, Munich, Germany), rat anti
mouse F4/80 and rat anti mouse CD11b (Serotec,
Oxford, UK). Specificity of the immunoreaction was
assessed by omission of the primary antibody.
For Nissl stains spinal cord, cerebral cortex and striatal
sections were immersion fixed in 0.1 M PBS containing
4 % paraformaldehyde for 10 min followed by incubation
with 0.1 % cresyl violet for 10 min, rinsing, dehydration
and mounting for light microscopy.
Quantification of the number of macrophages, micro-
glia and neurons was performed with a light microscope
(Olympus BH2, Olympus, Hamburg, Germany) using an
ocular grid covering a defined area (0.0256 mm2) at a
final magnification of 600×. Neurofilament and MPZ
staining intensities were measured by optical densitom-
etry using the MetaVue program, version 6.3r2 (Visitron
Systems, Munich, Germany).
Western blot analyses
After transcardial perfusion with PBS both striata were
dissected and snap frozen in liquid nitrogen. Tissue was
sonicated in radioimmunoprecipitation assay lysis buffer
(25 mM Tris-HCl pH 8, 10 mM Hepes, 150 mM NaCl,
145 mM KCl, 5 mM MgCl2, 2 mM EDTA, 0.1 % sodium
dodecyl sulphate, 1 % NP-40, 10 % glycerol). Protein con-
centration was determined by Lowry assay and proteins
were resolved by sodium dodecyl sulphate-polyacrylamide
gel electrophoresis, transferred to nitrocellulose mem-
branes and visualized using Ponceau S. Membranes were
blocked with Roti®-Block (Carl Roth) and probed with
respective antibody solutions overnight at 4 °C (DAT,
Millipore MAB369; D1 receptor, Santa Cruz, sc-1434; D2
receptor, Millipore, AB5084P; GAPDH, abcam, ab9484).
Incubation with horseradish peroxidase-conjugated
secondary antibodies was performed for 1 h at RT and
detection was achieved by use of ECL reagent and ECL
hyperfilm (GE Healthcare Bio-Sciences AB). Sequential
stainings were performed after incubating the nitrocellu-
lose membrane with stripping buffer (0.2 M glycine, 0.1 %
sodium dodecyl sulphate, 10 mM dithiothreitol, and 1 %
Tween) for 30–120 min. Completeness of removal of the
first set of primary antibodies was controlled by staining
with secondary antibodies. Different exposure times of
ECL hyperfilms were tested and the resulting signals were
quantified in the linear range by densitometry using NIH
ImageJ software. Results were normalized to naïve wt
littermate protein level as a reference and related to
GAPDH as loading control.
Semi-quantitative real-time PCR
Snap frozen midbrain was homogenized (ART-MICCRA
D-8, ART Labortechnik) in TRIzol® reagent. Total RNA
was isolated according to the guidelines of manufacturers.
Concentration and quality of RNA was determined using a
BioPhotometer and 1 μg of RNA was reverse transcribed in
a 100 μl reaction using random hexamer primers.
Complementary DNA samples were subsequently analyzed
as triplicates by semi-quanitiative real-time polymerase
chain reaction using pre-developed TaqMan® assays
(Mm00438388_m1) and TaqMan® universal PCR master
mix (Applied Biosystems). Results were normalized to a
reference naïve wt mRNA level.
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Autoradiography
FP-CIT (0.74 MBq) was injected via tail vein 20 min before
euthanasia. The brain was taken out, then immediately
frozen and cut into 20-μm coronal slices. Autoradiography
plates were exposed to the slices immediately for 45 min
for visualization of FP-CIT distribution with a digital
autoradiography system (CR 35 Bio; Raytest). In order to
quantify tracer uptake distribution, regions of interests
(ROIs) were drawn manually at the striatum.
Striatal dopamine analysis by high performance liquid
chromatography (HPLC)
Striata were homogenized with Branson Digital Sonifier (G.
Heinemann Ultraschall- und Labortechnik, Schwäbisch-
Gmünd, Germany) in ice-cold aqueous solution of
H3PO4 (150 mM) and DTPA (500 μM). The hom-
ogenate was then centrifuged at 40700 g for 20 min
at 4 °C. Aliquots (50 μl) of the obtained supernatant
were chromatographed on a Nucleosil 100-5 C18
column (250 mm x 4.6 mm; 5 μm) (Macherey-Nagel,
Düren, Germany). The separation was done in
isocratic elution mode at room temperature using
mobile phase containing 0.02 M sodium citrate,
0.1 mM EDTA, 0.01 M sodium phosphate, 0.003 M
octanesulphonic acid, 0.003 M heptanesulphonic acid,
7 % acetonitrile, and 3 % methanol at a pH adjusted
to 3.1 with diethylamine. For external standard, a
stock solution containing 500 μg/ml dopamine,
homovanillic acid, and 3,4-dihydrophenylacetic acid
(Sigma-Aldrich, Steinheim, Germany) was prepared.
The chromatography system consisted of an Agilent
1100 Series isocratic pump, a thermostatted autosam-
pler, a thermostatted column compartment and a
Bio-Rad 1640 electrochemical detector with glassy
carbon electrode. The measurements were done at an
electrode potential of +0.72 V versus the Ag/AgCl
reference electrode. Results were normalized to refer-
ence naïve wt neurotransmitter level.
Statistical analysis
For statistical analysis of behavioral data, the distribu-
tion of the values was investigated via Q-Q-plots.
None of the plots showed normal distribution, thus
non-parametric methods were employed as statistical
tests. To compare two groups for each timepoint, the
Mann-Whitney Test was used. As several time points
were investigated Bonferroni-Holm correction was ap-
plied (§). To implement the change over time into
the statistical analyses, we calculated the difference to
the pre-operative values. For the figures, mean values
± SEM intervals as error bars are shown. Additionally,
Cohens d as effect size measure was calculated for
interpretation of the size of the effect in Fig. 1c. To
interpret Cohens d data, values lower than 0.5 show a
small effect, values between 0.5 to 0.8 represent a medium
effect and values higher than 0.8 imply a large effect [12].
Statistical analysis was done with software R version 3.2.2.
*p < 0.05, **p < 0.01, ***p < 0.001 were considered as
significant p-values.
For data examination of immunohistochemistry,
protein analysis and rt-PCR analysis we used the
parametric one-way ANOVA with posthoc Tukey test.
*p < 0.05, **p < 0.01, ***p < 0.001 were considered as
significant p-values.
Results
Tor1a+/- mice develop more severe dystonia-like move-
ments than wt mice after sciatic nerve crush
Two days after nerve injury, tail suspension tests re-
vealed severe weakness of sciatic nerve innervated mus-
cles leading to extension of the right hind leg (Fig. 1a).
At later time points, repetitive, involuntary muscle con-
tractions with clenching of the toes and retraction of the
affected leg were detected in both wt and Tor1a+/- mice
resembling focal dystonia-like movements (Fig. 1b) with
a peak at four weeks after surgery followed by a continu-
ous slow decrease of the DLMS in both genotypes. The
score values were significantly higher as compared to
sham operated controls that did not reveal abnormal
movements and posturing (Fig. 1c). However, the
frequency and duration of dystonia-like movements after
nerve injury was higher in Tor1a+/- mutants as
compared to wt mice with statistical significance at
weeks four and eight after surgery (p < 0.05). Calculation
of the effect size by Cohens d showed a small to medium
effect of the genetic mutation in Tor1a+/- mice.
Despite the initial profound weakness due to the
peripheral nerve lesion gait analyses demonstrated a
slight but significantly impaired interpaw coordination
in mutant mice as compared to wt mice at week 6 and 8
using the CatWalk system, while the overall motor per-
formance on the rotarod test was rather mildly impaired
in both genotypes showing no differences between both
groups. Because of the complexity of the rodent walking
pattern, even subtle changes in the motor performance
of mice with dystonia-like movements could be detected
demonstrating that kinematic gait analysis is the most
appropriate method for quantifying the motor pheno-
type (Fig. 1d,e).
Structural and functional recovery of the sciatic nerve is
not different after crush injury between Tor1a+/- and wt
mice
Baseline electrophysiological and immunohistological
analysis comparing naïve wt with Tor1a+/- mice did not
reveal any differences in sciatic nerve structure or func-
tion. Three days after nerve crush a complete conduc-
tion failure across the lesion was found in sciatic nerves
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of either genotype (data not shown). After six weeks
compound action potential amplitudes (CMAP) as well
as nerve conduction velocities (NCV) had recovered in
wt and mutant mice by about half the pre-crush level
with numerous low amplitude late and polyphasic
potentials still present (Fig. 2a-c). Although CMAPs and
NCVs were still lower at this time point as compared to
control mice, the differences were not significant. There
was no significant reduction of CMAP or NCV in sham
operated mice (Fig. 2b,c). In addition immunohisto-
chemical stainings of naïve wt and Tor1a+/- mouse sci-
atic nerves displayed the same optical density of myelin
protein zero (MPZ)(Fig. 2d) and neurofilament
(NF)(Fig. 2e) without obvious changes eight weeks after
crush injury. Analyses of inflammatory cell numbers in
wt and Tor1a+/- mice sciatic nerves displayed a similar
trend but non-significant increase of F4/80+ macro-
phages in wt and mutant mice eight weeks after crush
injury as compared to naïve animals (Fig. 2f ).
Neuronal cell density is unchanged in Tor1a+/- as
compared to wt mouse spinal cord and brain
Next, we examined the somatosensory cortex, striatum
and the spinal cord (L2-4) for structural alterations.
Nissl staining in cerebral cortex (Fig. 3a,e) striatum
(Fig. 3b,f ) and ipsilateral spinal cord (Fig. 3c,g)
Fig. 1 Tail suspension test shows focal dystonia-like movements in wt and Tor1+/- mice that is induced by sciatic nerve crush. a, b Images of a
Tor1a+/- mouse 2 days and 2 weeks after sciatic nerve crush of the right hind leg. Typical defect is shown when muscles of the affected leg are
still profoundly weak. Therefore, the degree of dystonia-like postures (b) may be even underrated at this early timepoint of 2 weeks. c Temporal
evolution of abnormal movements on the DMLS of the right hind leg measured during tail suspension in crush-injured Tor1a+/- mice (grey line;
n = 33) and wt mice (black line; n = 30) as well as sham operated Tor1a+/- (dotted grey line; n = 8) and wt mice (dotted black line; n = 8) during
an observation time of 8 weeks. Mean values for each time point ± SEM are shown. d Gait analysis displaying the step sequence regularity index
(percentage) as measurement of the interpaw-coordination during ambulation in crush-injured Tor1a+/- (grey line; n = 30) and wt mice (black line;
n = 23) as well as sham operated Tor1a+/- (dotted grey line; n = 8) and wt mice (dotted black line n = 8)(mean ± SEM). Before sciatic nerve injury a
normal step sequence regularity index in both genotypes was observed, reflecting a normal interpaw-coordination during ambulation. One week after
trauma the regularity index decreased in all groups with greater impairment in crush injured than in sham operated mice. While sham operated wt or
Tor1a+/- mice as well as crush injured wt mice recovered with time, the Tor1a+/- crush group did not, leading to a significant reduction of step sequence
regularity index at week 6 an 8 (p< 0.05; p< 0.01 respectively) compared to crush injured wt mice. e Diagram showing results of the rotarod performance
test (grey line, Tor1a+/- crush n= 23; black line, wt crush n= 19; dotted grey line, Tor1a+/- sham n= 8, dotted black line, wt sham n= 8)(mean ± SEM). The
motor impairment of Tor1a+/- mice after recovering from the nerve crush was subtle during spontaneous motor behavior and did not manifest in a
rotarod analysis. * and ** denote significant differences (p< 0.05 and p< 0.01 respectively) comparing nerve injured Tor1a+/- and wt mice for one time
point (non-parametric two-tailed Mann-Whitney test). § demonstrates a significant difference after Bonferroni-Holm correction of the p-values for the whole
time span of 8 weeks
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Fig. 2 Tor1a+/- and wt mice do not show structural differences in the peripheral nervous system, spinal cord and brain. a Representative
examples of a nerve conduction study in wt and Tor1a+/- control (left) and crush injured (right) mouse sciatic nerves. Magnification of proximal
compound action potential in wt and Tor1a+/- crush injured mice illustrates abundant polyphasic late potentials indicating slowly conducting
nerve fibre populations. b, c Functional analysis of sciatic nerves by nerve conduction study at the operated ipsilateral (light grey) and the
unoperated contralateral (dark grey) side in Tor1a+/- and wt mice with sciatic nerve crush or sham injury. Parameters of interest (mean ± SD) are
(b) compound muscle action potential (CMAP) and (c) the nerve conduction velocity (NCV). d, e Diagrams showing optical density of
immunohistochemical staining against (d) myelin protein zero (MPZ) and (e) neurofilament (NF) (mean ± SEM). f Diagram showing number of
F4/80+ macrophages/mm2 (mean ± SEM) in sciatic nerves of naïve wt, naïve Tor1a+/-, crush injured wt and Tor1a+/- mice. n = number of mice
are depicted below the diagrams. Statistical analysis was performed by using the parametric one-way ANOVA with posthoc Tukey test
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Fig. 3 Tor1a+/- mice do not present morphological changes in brain and spinal cord after crush injury. a-c Representative images of Nissl stained
neurons in (a) somatosensory cortex, (b) striatum and (c) spinal cord of naïve wt, naive Tor1a+/-, wt crush and Tor1a+/- crush injured mice. High
magnification inserts of single cells are included in each image. d Representative images of CD11b +microglia in spinal cord. e-g Diagrams
showing Nissl + profiles per mm2 in (e) cortex and (f) striatum of the respective groups of mice ipsilateral and contralateral to the sciatic nerve
crush injury and (g) ipsilateral spinal cord (mean ± SEM). h Number of CD11b + cells per mm2 of the different groups of mice in white (wm) and
grey matter (gm) are shown (mean ± SEM). n = number of mice are shown below the diagrams. Statistical analysis was performed by using the
parametric one-way ANOVA with posthoc Tukey test
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excluded gross structural differences. CD11b +
microglia within the white and grey matter of the
spinal cord did not show significantly different cell
numbers in naïve and nerve crushed wt and Tor1a+/-
mice (Fig. 3d,h).
Abnormal central dopaminergic neurotransmission after
sciatic nerve injury correlates with dystonia-like
phenotype in Tor1a+/- mice
We next focused on the central dopaminergic system,
since torsinA has been associated with dopaminergic
neurotransmission and because striatal dopaminergic
imbalance could be a cause of dystonia.
Untreated Tor1a+/- mice showed an about 40 %
reduction of striatal presynaptic DA transporter (DAT)
as compared to wt mice at the protein level (p < 0.001).
Eight weeks after nerve injury, a significant decrease of
DAT from baseline was observed in the striatum of wt
animals contralateral to the nerve crush lesion while a
significant increase of DAT protein was found in Tor1a
+/- mice (Fig. 4a,b). Comparable changes in DAT mRNA
levels were noted within the contralateral midbrain indi-
cating that alteration in DAT expression occurs at the
transcriptional level (Fig. 4c). Striatal DAT autoradiog-
raphy as a measure for presynaptic dopaminergic func-
tion showed a trend but no significant elevation of DAT
binding in untreated Tor1a+/- versus wt mice. DAT
binding decreased significantly in mutant mice eight
weeks after sciatic nerve crush, while no change
occurred in wt (Fig. 4d,e).
Measurements of striatal DA and its metabolite
homovanilic acid (HVA) by HPLC of the contralateral
striatum showed an about 40 % reduction of DA level in
naïve mutant mice as compared to wt mice (p < 0.01).
Eight weeks after crush injury DA level were diminished
by about 50 % in wt mice (p < 0.01) and appeared mildly
increased in Tor1a+/- but this was not significant
(Fig. 4f ). HVA levels also only showed a trend towards a
slight increase from baseline in Tor1a+/- mice eight
weeks after crush injury which was again not significant
(Fig. 4g).
We did not find any differences in DA D1 and D2
receptor protein expression in wt and mutant mice at
baseline. Only after sciatic nerve crush a 25 % to 35 %
(p < 0.01) decline of D1 and D2 receptor proteins was
found in both wt and Tor1a+/- mice on the contralateral
striatum (Fig. 4h ,i), but not in the ipsilateral striatum
(Fig. 4j,k)
Pharmacological manipulation of the dopaminergic
system influences the dystonia-like phenotype in Tor1a+/-
but not wt mice
We questioned whether the observed striatal DA dysreg-
ulation was a cause or consequence to the development
of post-crush dystonia-like movements in Tor1a+/-
mice. To answer this question we performed two
additional experiments: First we induced central DA
depletion using alpha-methyl-p-tyrosine (AMPT) and
secondly we challenged mice with the DA precursor
L-Dopa/benserazide to increase striatal DA levels. To
evaluate the treatment response behavioral analyses were
done and striatal DA levels were measured. Chronic
treatment of Tor1a+/- mice with AMPT led to a
significant reduction of the DLMS score starting 4 weeks
after crush injury in comparison to untreated mutant
mice. In contrast, repeated L-Dopa/benserazide injec-
tions induced a significant higher DLMS score in mutant
mice from week six on (Fig. 5a). In wt mice however,
L-Dopa or AMPT therapy did not lead to any significant
changes in DLMS scores (Fig. 5b). Neurochemically,
AMPT treatment resulted in a significant reduction of
the elevation of DA and HVA observed in prior experi-
ments one day after nerve crush in Tor1a+/- mice.
L-Dopa/benserazide injection analyzed 90 min after
administration even led to a further increase of HVA as
compared to the one day post nerve crush situation
(Fig. 5c,d). In contrast, we did not observe a significant
elevation of the DA or HVA level in wt mice one day
after nerve injury as compared to control mice. 90 min
after L-Dopa administration, DA level in wt mice was
again comparable to baseline control (Fig. 5e,f ).
Discussion
We describe an abnormal motor behavior in Tor1a+/-
mice after peripheral nerve injury, that fits very well to
the phenotypical description of dystonia based on the
latest consensus definition [2]. Within the first 2 weeks
after the peripheral nerve injury both wt and Tor1a+/-
mice developed abnormal posturing and distorted move-
ments resembling pseudodystonia described in humans
after limb deafferentation [2]. At later timepoints, during
sensorimotor recovery, however, the severity of dystonia-
like movements was more pronounced in mutant mice
and only in Tor1a+/- mice sensitive to pharmacological
modulation of central dopaminergic neurotransmission.
Moreover, in Tor1a+/- mice the appearance of dystonia-
like movements was associated with functional impair-
ment of the gait pattern that was still present after
8 weeks indicating a predisposition to consolidate this
movement disorder. In contrast, abnormal movements
in wt mice were significantly less severe and were
accompanied by only transient and mild gait impairment
likely due to peripheral denervation alone.
Several lines of evidence suggest that an altered dopa-
minergic neurotransmission in Tor1a+/- mice may rep-
resent the endogenous predisposition for the observed
intensified and prolonged dystonia-like movements in
response to nerve injury. This assumption is based on
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Fig. 4 (See legend on next page.)
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(See figure on previous page.)
Fig. 4 Dopamine metabolism is disturbed in Tor1a+/- mice. a Representative Western blot of striatal DAT, DA D1 and DA D2 receptors in naïve
wt, naïve Tor1a+/, crush injured wt and crush injured Tor1a+/- mice. GAPDH is used as loading control. b Relative DAT, (h) DA D1 receptor and
(i) DA D2 receptor protein levels in striatum contralateral to crush injury are shown (mean ± SD) comparing wt (blue) and Tor1a+/- (orange) mice
before and 8 weeks after crush injury. c Diagram demonstrates relative DAT mRNA expression by real-time PCR in midbrain contralateral to crush
injury in wt and Tor1a+/- mice before and 8 weeks after sciatic nerve crush (mean ± SD). d Representative images of in-vivo DAT autoradiography
with FP-CIT in Tor1a+/- control (left) and crush injured mutant (right). e Diagram shows mean striatal DAT binding counts in wt and Tor1a+/-
mice before and 8 weeks after sciatic nerve crush (mean ± SD). f, g Relative striatal DA and HVA levels measured by HPLC are shown in wt and
Tor1a+/- mice before and 8 weeks after crush injury contralateral to nerve crush (mean ± SD). j, k Ipsilateral DA D1 and DA D2 receptor relative
protein levels are demonstrated in wt and Tor1a+/- mice before and 8 weeks after crush injury (mean ± SD). n = number of mice are depicted
below the diagrams (wt/Tor1a+/-). Statistical analysis was performed by using the parametric one-way ANOVA with posthoc Tukey test. *p < 0.05,
**p < 0.01, ***p < 0.001
Fig. 5 Pharmacologic modulation of the central dopaminergic system influences dystonia-like phenotype in Tor1a+/- but not wt mice. a Diagram
demonstrates abnormal movements measured by the DLMS of Tor1a + -/ mice before and after sciatic nerve crush during an observation time of
8 weeks. 3 groups of mice are investigated: Naïve mutant mice (dark grey line; n = 33), Tor1a+/- mice treated with AMPT (light grey line; n = 13)
and L-Dopa/benserazide (black line; n = 14) (mean ± SEM). b Focal DLM score of 3 groups of wt mice before and after sciatic nerve crush is shown
(naïve mice - dark grey line, n = 30; AMPT treated mice – light grey line, n = 9; L-Dopa/benserazide treated mice – black line, n = 10) (mean ±
SEM). § demonstrates a significant difference after Bonferroni-Holm correction of the p-values (non-parametric two-tailed Mann-Whitney test) for
the whole time span of 8 weeks comparing either (a) naïve nerve injured Tor1a+/- or (b) wt mice with AMPT or L-Dopa/benserazide treated mice
of the same genotype for all time points. c, d Diagrams show (c) relative DA and (d) HVA level contralateral to the crush injury side of naïve
(n = 6) and Tor1a+/- mice 1 day after nerve crush (n = 5) as well as crush injured mutant mice that received either AMPT (4 h after injection of the
last of 3 AMPT administrations, n = 5) or L-Dopa/benserazide treatment (90 min after injection of L-Dopa, n = 5) (mean ± SD). e, f Diagrams
demonstrate (e) relative DA and (f) HVA level contralateral to the crush injury in wt mice that were treated with either AMPT (n = 5) or L-Dopa/
benserazide treatment (n = 5) (mean ± SD). Statistical analysis was performed by using the parametric one-way ANOVA with posthoc Tukey test.
*p < 0.05, **p < 0.01
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two observations: (1) Tor1a+/- mice were characterized
by a hypodopaminergic state at baseline as compared to
wt mice and (2) a paradoxical increase of dopaminergic
neurotransmission was shown in response to the nerve
injury as reflected by an upregulation of presynaptic
DAT, an increased DA metabolism and downregulation
of D1 and D2 receptors. These alterations were opposed
to the striatal dopaminergic downregulation of wt mice
during sensorimotor recovery from the sciatic nerve
lesion. It has been shown that electrical (sensory) stimu-
lation of the rat forepaw inhibits striatal DA release con-
ceivably by activation of striatal GABA-ergic striatal
interneurons by glutamate [11]. We assume that in wt
mice at least partially comparable mechanisms led to
chronic downregulation of striatal DA and DAT after
nerve crush with a constant sensory stimulus due to the
nerve injury during the recovery phase. We hypothesize
that Tor1a+/- mice on the other hand present a deficit
in central inhibition that drives uncontrolled central DA
efflux after peripheral nerve injury. Indeed, impaired
central GABA-ergic control leading to disinhibition of
the sensorimotor system has been suggested as a
pathogenetic mechanism of dystonia based on data from
a DYT1 mouse model, the dtsz mutant hamster but also
from DYT1 carriers and sporadic dystonia patients [18,
22, 47]. In the latter study a reduction in GABA receptor
affinity in C11-flumazenil (a selective GABA(A) receptor
ligand) positron emission tomography (PET) was
observed [18].
In proof of principle experiments, we used established
pharmacological treatments to suggest a causal link
between the observed imbalance in the basal ganglia-
thalamo-cortical network with focal dystonia-like
movements in the previously injured limb. By treating
Tor1a+/- mice with either L-Dopa or the DA synthesis
blocker AMPT we could drive striatal DA concentra-
tions into opposite directions and either aggravate or
reduce dystonia-like movements in the mutant mice as
compared to those observed with no treatment. In con-
trast, abnormal movements in wt mice did not respond
significantly to dopaminergic modulation. This supports
the notion that the motor symptoms in wt mice reflect
peripheral pseudodystonia as result of peripheral
deafferentation rather than central dystonia as the
observed phenotype in mutant mice. The analyses of the
dopaminergic metabolism after L-Dopa administration
suggested a compensatory mechanism to preserve
dopamine homeostasis and prevent a hyperdopaminergic
striatal environment in wt mice as opposed to Tor1a+/-
mice. Dopaminergic nigrostriatal input is crucial for
motor function and regulates the activity in the direct
and indirect basal ganglia pathway via DA D1 and D2
receptors. Alterations of neurochemical metabolism have
been detected in different mouse models for DYT1
dystonia demonstrating substantial discordance concern-
ing dopaminergic changes. Complementary to the find-
ings in Tor1a+/- mice, DYT1 knock-down mice showed
a slight but not significant decrease in striatal DA while
in a transgenic DYT1 mouse model containing human
wt torsinA striatal DA was significantly reduced [15, 21].
However, in contrast to our findings in Tor1a+/- mice a
DYT1 transgenic model overexpressing human ΔE-torsinA
developed increased striatal DA levels by 18 % in asymp-
tomatic and a decrease by 39 % in symptomatic animals
showing abnormal movements [50]. DYT1 knock-in mice
and hΔGAG transgenic mice on the other hand did not
exhibit changes in striatal DA and DOPAC level [14, 21].
In principle, the role of striatal dopaminergic neurotrans-
mission as an important modifier for the manifestation of
dystonia in a multistep pathophysiological pathway is
widely accepted already because inherited defects of DA
synthesis or acquired alterations of DA neurotransmission,
such as in Parkinson’s disease or with pharmacotherapy
altering dopaminergic neurotransmission [10, 42] are well
known causes of dystonia. Moreover, mutations in genes
involved in the biosynthesis of DA encoding GTP cyclohy-
droxylase (DYT5), sepiapterin reductase and tyrosine
hydroxylase cause dopa-responsive dystonia [27, 32].
Additionally, GNAL (DYT25) that encodes the stimulatory
α subunit of a G-protein (Gαolf), has also been linked to
DA signaling because it was shown to be necessary for D1
receptor coupling [13]. A novel finding in our experiments,
however, is the abnormal dynamic response of striatal DA
neurotransmission in Tor1a+/- mice during sensorimotor
recovery from a peripheral nerve injury, which may offer an
attractive link between inherited predisposition and
environmental triggers of DYT1 dystonia. Dopaminergic
nigrostriatal input regulates the activity in the direct and
indirect basal ganglia pathway via D1 and D2 receptors. In-
deed, the nigrostriatal dopaminergic fibers terminate on the
shafts of the dendritic spines of the medium spiny neurons
(MSN) and the cortical afferents terminate on the heads of
spines, enabling DA modulation of the corticostriatal input.
Alterations of DA dependent synaptic plasticity in medium
spiny neurons have been implicated in the basal ganglia
network dysfunction associated with several psychiatric or
neurological diseases [7], in particular L-Dopa induced
dyskinesia in Parkinson’s disease [10]. A common disease
mechanism could be the inability of the striatum to filter
neuronal signals once the activities of direct and indirect
basal ganglia pathways become unbalanced due to
abnormal DA-mediated MSN function [7].
The molecular mechanism of an abnormal striatal DA
homeostasis in Tor1a+/- mice could not be addressed by
our methods, but an increased dopaminergic neuro-
transmission in response to the nerve crush against the
background of a baseline hypodopaminergic state resem-
bles the mechanism of dyskinesia development in
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Parkinson’s disease. Dyskinesia are thought to result
from sensitization of postsynaptic DA receptors through
large swings in striatal extracellular DA concentration
with fluctuating L-Dopa plasma levels [10]. Presynaptic
mechanisms, in particular DAT reuptake, play an
important role in maintaining an extracellular DA
homeostasis [1] and the reduced availability of DAT with
presynaptic degeneration is one major cause of pulsatile
dopaminergic neurotransmission in Parkinson’s disease
[10]. Indeed, although DAT protein levels were increased
in Tor1a+/- mice after crush injury, our autoradiography
data suggest a malfunction of DAT with impaired
capability to utilize DA since DAT-ligand binding by
FP-CIT was significantly lower after crush injury than
before. Another possible explanation why a 50 % re-
duced torsinA level in Tor1a+/- mice might affect DAT
function could be a reduced availability of DAT at
presynaptic membranes. TorsinA has been shown to
regulate cellular trafficking of DAT to the plasma
membrane thus affecting DA uptake [54]. A defective
DA reuptake however, is not uniformly described. One
DYT1 mouse model did not present any changes in
striatal DAT or D1/D2 receptor binding- Yet, these
animals still presented with an attenuated motor
response to amphetamine administration suggesting a
DA release problem [5]. Presynaptic release deficits of
neurotransmitter have also been observed in brain slices
of a DYT1 mouse model [58]. Other studies emphasized
a disturbed D1 and D2 receptor function in DYT1
models [47, 48, 59] linking the D2-receptors to disinhib-
ition of striatal GABAergic synaptic activity [47] and
imbalanced dopaminergic to cholinergic signaling [48].
Collectively, a wealth of preclinical data links DYT1
dystonia to impaired striatal DA transmission and this is
in keeping with our findings in mutant mice. Still, the
exact synaptic mechanisms need to be addressed in
future studies. Clinical data also suggest dopaminergic
disturbances in dystonia. Radioligand neuroimaging of
the dopaminergic system in patients with isolated
dystonia of mixed etiology revealed reduced D2 receptor
binding and mildly reduced DA metabolism in
[18F]Dopa PET [35, 41, 43]. DYT1 mutation carriers also
presented reduced striatal D2 receptor binding
compared to normal controls [3]. The few available post
mortem analyses of DYT1 brains though provided only
subtle evidence of impaired DA neurotransmission, such
as a mild reduction of striatal DA level [17] or a higher
DA turnover in the striatum [4]. However, in keeping
with our observation of an increase in DA neurotrans-
mission in nerve injured, dystonic Tor1a+/- mice
approaching wt baseline level, one would expect none or
only mild DA metabolic changes comparing dystonia
manifesting DYT1 patients with healthy subjects. DA
neurotransmission changes in dystonia are likely just one
step within a complex cascade of secondary maladaptive
plasticity of the central network in Tor1a+/- mice. Indeed,
deficits of striatal synaptic plasticity with loss of inhibition
have been found in DYT1 mouse and rat models [20, 33]
and these were connected to partial D2 receptor dysfunc-
tion [33, 34]. Furthermore maladaptive motor cortical
plasticity has been correlated to dystonia in patients with
task-specific focal dystonia like writer’s cramp and
musician’s dystonia [23, 44]. In addition FDG-PET studies
on DYT1 patients revealed metabolic network abnormal-
ities in basal ganglia, cerebellum and motor areas [9, 16]
and similar alterations in cerebral glucose metabolism
were also found in Tor1a+/- mice [56]. Triggering
dystonia in a DYT1 knock-in model using mitochondrial
complex-II inhibition as a metabolic stressor has not been
successful [6]. In contrast, the nerve injury in our present
experiments leads to compensatory neuronal plasticity
[36, 40]. Thus, we aimed to disturb central sensorimotor
integration and to challenge the adaptive capabilities of
the central motor network.
Conclusions
In summary, we were able to link the genetic defect of
reduced torsinA expression in a DYT1 related mouse
model to a maladaptive response of the striatal dopamin-
ergic system after a peripheral nerve lesion and to the
manifestation of dystonia-like movements. Our findings
raise the interesting possibility, that preventive antidopa-
minergic treatment could reduce the risk of manifesting
dystonia in patients carrying the DYT1 mutation.
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